A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bojsen, Rasmus ^a   Regenberg, Birgitte ^b   Gresham, David ^c   Folkesson, Anders ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ERGOSTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RAS PROTEIN; RAS1 PROTEIN, S CEREVISIAE; RAS2 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN; TOR1 PROTEIN, S CEREVISIAE; TORC1 PROTEIN COMPLEX, S CEREVISIAE; TRANSCRIPTION FACTOR;

ANTAGONISTS AND INHIBITORS; ANTIFUNGAL RESISTANCE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; DNA SEQUENCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MUTATION; PLANKTON; RIBOSOME; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDA GLABRATA; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; GENE EXPRESSION REGULATION, FUNGAL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PLANKTON; RAS PROTEINS; RIBOSOMES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 84959420732     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21874     Document Type: Article

References (51)

1. Richardson, M. D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 Suppl 1, i5-i11 (2005).
2. Ramage, G., Martinez, J. P., Lopez-Ribot, J. L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6, 979-86 (2006).
3. Bachmann, S. P. et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46, 3591-6 (2002).
4. Kuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., Ghannoum, M. A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46, 1773-80 (2002).
5. Mesa-Arango, A. C., Scorzoni, L., Zaragoza, O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol 3, 286 (2012).
6. Hitchcock, C. A., Barrett-Bee, K. J., Russell, N. J. The lipid composition and permeability to azole of an azole-and polyene-resistant mutant of Candida albicans. J Med Vet Mycol 25, 29-37 (1987).
7. Nett, J. et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 51, 510-20 (2007).
8. Nett, J. E., Crawford, K., Marchillo, K., Andes, D. R. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 54, 3505-8 (2010).
9. Martins, M., Henriques, M., Lopez-Ribot, J. L., Oliveira, R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 55, 80-5 (2012).
10. Mukherjee, P. K., Chandra, J., Kuhn, D. M., Ghannoum, M. A. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71, 4333-40 (2003).
11. Khot, P. D., Suci, P. A., Miller, R. L., Nelson, R. D., Tyler, B. J. A small subpopulation of blastospores in candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes. Antimicrob Agents Chemother 50, 3708-16 (2006).
12. LaFleur, M. D., Kumamoto, C. A., Lewis, K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50, 3839-46 (2006).
13. Lewis, K. Persister cells. Annu Rev Microbiol 64, 357-72 (2010).
14. Al-Dhaheri, R. S., Douglas, L. J. Apoptosis in Candida biofilms exposed to amphotericin B. J Med Microbiol 59, 149-57 (2010).
15. Bink, A. et al. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob Agents Chemother 55, 4033-7 (2011).
16. Coates, A. R. M. Dormancy and Low-Growth States in Microbial Disease, 292 (Cambridge University Press 2003).
17. Bojsen, R., Regenberg, B., Folkesson, A. Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase. BMC Microbiol 14, 305 (2014).
18. Spoering, A. L., Lewis, K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 183, 6746-51 (2001).
19. Anderl, J. N., Zahller, J., Roe, F., Stewart, P. S. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 47, 1251-6 (2003).
20. Reynolds, T. B., Fink, G. R. Bakers' yeast, a model for fungal biofilm formation. Science 291, 878-81 (2001).
21. Ryan, O. et al. Global gene deletion analysis exploring yeast filamentous growth. Science 337, 1353-6 (2012).
22. Vandenbosch, D. et al. Genomewide screening for genes involved in biofilm formation and miconazole susceptibility in Saccharomyces cerevisiae. FEMS Yeast Res 13, 720-30 (2013).
23. Giaever, G. et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387-91 (2002).
24. Andersen, K. S. et al. Genetic Basis for Saccharomyces cerevisiae Biofilm in Liquid Medium. G3 (Bethesda) 4, 1671-1680 (2014).
25. Smith, A. M. et al. Quantitative phenotyping via deep barcode sequencing. Genome Res 19, 1836-42 (2009).
26. Robinson, D. G., Chen, W., Storey, J. D., Gresham, D. Design and analysis of Bar-seq experiments. G3 (Bethesda) 4, 11-8 (2014).
27. Robinson, M. D., McCarthy, D. J., Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-40 (2010).
28. Cherry, J. M. et al. Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids Res 40, D700-5 (2012).
29. Martel, C. M. et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother 54, 3578-83 (2010).
30. Sreenivasan, A., Kellogg, D. The elm1 kinase functions in a mitotic signaling network in budding yeast. Mol Cell Biol 19, 7983-94 (1999).
31. Loewith, R., Hall, M. N. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 189, 1177-201 (2011).
32. Dubouloz, F., Deloche, O., Wanke, V., Cameroni, E., De Virgilio, C. The TOR and EGO protein complexes orchestrate microautophagy in yeast. Mol Cell 19, 15-26 (2005).
33. Wullschleger, S., Loewith, R., Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-84 (2006).
34. Barbet, N. C. et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7, 25-42 (1996).
35. Martin, D. E., Soulard, A., Hall, M. N. TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell 119, 969-79 (2004).
36. Lafleur, M. D., Qi, Q., Lewis, K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 54, 39-44 (2010).
37. Belenky, P., Camacho, D., Collins, J. J. Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep 3, 350-8 (2013).
38. Phillips, A. J., Crowe, J. D., Ramsdale, M. Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 103, 726-31 (2006).
39. Allen, C. et al. Isolation of quiescent and nonquiescent cells from yeast stationary-phase cultures. J Cell Biol 174, 89-100 (2006).
40. Aragon, A. D. et al. Characterization of differentiated quiescent and nonquiescent cells in yeast stationary-phase cultures. Mol Biol Cell 19, 1271-80 (2008).
41. Allison, K. R., Brynildsen, M. P., Collins, J. J. Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol 14, 593-8 (2011).
42. Johnson, P. J., Levin, B. R. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet 9, e1003123 (2013).
43. Nguyen, D. et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334, 982-6 (2011).
44. Ramage, G., Robertson, S. N., Williams, C. Strength in numbers: antifungal strategies against fungal biofilms. Int J Antimicrob Agents 43, 114-20 (2014).
45. Dahlan, R., Patel, A., Haider, S. Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus. Can J Infect Dis Med Microbiol 23, e44-7 (2012).
46. Hashemi, S. B. et al. Endogenous Aspergillus endophthalmitis occurring after liver transplantation: a case report. Transplant Proc 41, 2933-5 (2009).
47. Vakil, R., Knilans, K., Andes, D., Kwon, G. S. Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Pharm Res 25, 2056-64 (2008).
48. Dannaoui, E., Schwarz, P., Lortholary, O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 53, 3549-51 (2009).
49. Ernst, E. J., Yodoi, K., Roling, E. E., Klepser, M. E. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 46, 578-81 (2002).
50. EUCAST. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14, 398-405 (2008).
51. Anders, S. et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc 8, 1765-86 (2013).